Impact News +++ SThree shares plunge 22% as fees slide; firm warns slowdown to persist into FY26 (Investing.com) +++ STHREE Aktie -10,42%

IPSEN Aktie

>IPSEN Aktienkurs

118.4 EUR +0.2% (Tradegate)

Ask: 117.8 EUR / 42 Stück

Bid: 117.5 EUR / 42 Stück

Tagesumsatz: 1 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IPSEN Aktie über LYNX handeln

Intraday

1 Jahr

>IPSEN Performance

1 Woche: +1,2%

1 Monat: +6,6%

3 Monate: +15,4%

6 Monate: +8,9%

1 Jahr: +13,5%

laufendes Jahr: +8,3%

>IPSEN Aktie

Name:

IPSEN S.A. PORT. EO 1

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0010259150 / A0ESMG

Symbol/ Ticker:

I7G (Frankfurt)

Kürzel:

FRA:I7G, ETR:I7G, I7G:GR

Index:

Webseite:

https://www.ipsen.com/

Profil:

Ipsen S.A. is a global biopharmaceutical company s..
>Volltext..

Marktkapitalisierung:

9844.14 Mio. EUR

Unternehmenswert:

9362.23 Mio. EUR

Umsatz:

3575.09 Mio. EUR

EBITDA:

1600.26 Mio. EUR

Nettogewinn:

449.66 Mio. EUR

Gewinn je Aktie:

5.44 EUR

Schulden:

965.58 Mio. EUR

Liquide Mittel:

1450.68 Mio. EUR

Operativer Cashflow:

976.82 Mio. EUR

Bargeldquote:

1.02

Umsatzwachstum:

9.57%

Gewinnwachstum:

-34.25%

Dividende je Aktie:

1.4 EUR

Dividendenrendite:

1.18%

Dividendenschätzung:

1.18%

Div. Historie:

04.06.25 - 1.4€
30.05.24 - 1.2€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

IPSEN

Letzte Datenerhebung:

16.09.25

>IPSEN Kennzahlen

Aktien/ Unternehmen:

Aktien: 82.71 Mio. St.

Frei handelbar: 41.78%

Leerverk. Aktien: -

Rückkaufquote: 0.34%

Mitarbeiter: 5358

Umsatz/Mitarb.: 0.56 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 6.45%

Bewertung:

KGV: 22.22

KGV lG: 11.25

KUV: 2.8

KBV: 2.33

PEG-Ratio: -

EV/EBITDA: 5.85

Rentabilität:

Bruttomarge: 82.39%

Gewinnmarge: 12.58%

Operative Marge: 33.67%

Managementeffizenz:

Gesamtkaprendite: 6.7%

Eigenkaprendite: 10.82%

>IPSEN Peer Group

Es sind 70 Aktien bekannt.

>IPSEN Chart & Kurs - Tradegate

>IPSEN News

12.09.25 - 07:33

Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors (Business Wire)

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon. Dr. Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful drug CAPLYTA®, acquired by Johnson & Johnson for $14.6 billion in April 2025. Dr. Charles Kunsch, PhD, is a seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in pioneering biotech companies. Dr. Pascal Touchon, DVM, has over 40 years of international leadership in the biopharmaceutical industry, including key roles at Novartis Oncology and Atara Biotherapeutics and current board positions at Ipsen, CDR-Life, RoslinCT, Catalym and Xylocor. Philippe Guy, Chairman of Medincell's Board, said: “With the election o...

11.09.25 - 18:03	Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
	Monthly information relative to the total number of voting rights and shares composing the share capital...

09.09.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 36 - 2025 (GlobeNewswire EN)
	Attachment...

09.09.25 - 13:01	Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome (PR Newswire)
	Bylvay™ is the first and only medication approved in Canada for the treatment of both Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis TORONTO, Sept. 9, 2025 /PRNewswire/ -- Medison and Ipsen announced today that Health Canada has approved Bylvay™ (odevixibat) for the......

02.09.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025 (GlobeNewswire EN)
	Aggregated presentation by day and by market Statement of transactions in own shares from August 25th to August 29th 2025...

29.08.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025 (GlobeNewswire EN)
	Aggregated presentation by day and by market Statement of transactions in own shares from August 18th to August 22nd 2025...

27.08.25 - 18:03	Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire EN)
	Monthly information relative to the total number of voting rights and shares composing the share capital...

19.08.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025 (GlobeNewswire EN)
	...

12.08.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025 (GlobeNewswire EN)
	Attachment...

05.08.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

31.07.25 - 19:27	Ipsen S.A. reports 1H results, FY25 guidance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 18:03	Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) (GlobeNewswire EN)
	Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)...

31.07.25 - 13:27	Ipsen shares fall 6% as guidance raise overshadowed by product misses (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.25 - 10:30	Ipsen H1 Profit Rises On Sales Growth; Raises Annual Sales Outlook (AFX)
	PARIS (dpa-AFX) - Ipsen SA (IPSEY) Thursday reported net profit of 334 million euros or 4 euros per share for the first half, up from 232 million euros or 2.78 euros per share in the comparable pe......

29.07.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025 (GlobeNewswire EN)
	Attachment...

24.07.25 - 20:15	Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.07.25 - 19:45	Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors (GlobeNewswire EN)
	PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues....

23.07.25 - 07:33	Ipsen announces changes to its Executive Committee (GlobeNewswire EN)
	PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:...

22.07.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

16.07.25 - 18:03	IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025 (GlobeNewswire EN)
	Aggregated presentation by day and by market...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Entschulde dich durch Gott: Die Unschuld bleibt bewehrt und wird in Ewigkeit durch keine Glut verzehrt. - Angelus Silesius

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram